Virbac SA (FR:VIRP)
:VIRP
Top Page
Virbac SA
(VIRP)
Select Model
Select Model
Rating:68Neutral
Price Target:
€385.00
▲(7.24% Upside)
Action:DowngradedDate:03/19/26
The score is driven primarily by solid financial performance (growth, durable profitability, and a conservative balance sheet), tempered by weaker cash-flow conversion. Technical indicators are currently bearish/oversold, which drags the near-term outlook, while valuation is generally reasonable but supported by a low dividend yield.
Positive Factors
Revenue growth acceleration
Sustained and accelerating revenue through 2024–2025 signals durable demand across companion-animal and livestock segments. This supports longer-term topline resilience, funds product development and geographic expansion, and reduces dependency on short-term market swings.
Negative Factors
Weaker cash conversion
FCF falling to ~53% of net income highlights weaker cash conversion and potential working-capital or investment drains. Persistent below-par conversion can constrain organic reinvestment, dividend flexibility, and reduce buffer for strategic spending over the coming 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth acceleration
Sustained and accelerating revenue through 2024–2025 signals durable demand across companion-animal and livestock segments. This supports longer-term topline resilience, funds product development and geographic expansion, and reduces dependency on short-term market swings.
Read all positive factors
Virbac SA (VIRP) vs. iShares MSCI France ETF (EWQ)
Market Cap
€2.97B
Dividend Yield0.41%
Average Volume (3M)5.07K
Price to Earnings (P/E)11.0
Beta (1Y)0.63
Revenue Growth6.97%
EPS Growth-5.59%
CountryFR
Employees6,365
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)8.17
Shares Outstanding8,390,660
10 Day Avg. Volume4,115
30 Day Avg. Volume5,072
Financial Highlights & Ratios
PEG Ratio5.39
Price to Book (P/B)2.67
Price to Sales (P/S)2.05
P/FCF Ratio29.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€415.00Price Target Upside15.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)20.88
Revenue Forecast (FY)€1.56B
Virbac SA Business Overview & Revenue Model
Company Description
Virbac SA manufactures and sells a range of products and services for companion and food-producing animals in France, Europe, Latin America, North America, the Asia Pacific, the Middle East, and Africa. The company offers a range of vaccines, dent...
How the Company Makes Money
Virbac primarily makes money by selling animal health products across several categories and species, generating revenue from the commercial distribution of its portfolio through veterinary and agricultural channels. Key revenue streams include: (...
Virbac SA Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
82
Very Positive
Cash Flow
63
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.46B | 1.40B | 1.25B | 1.22B | 1.06B |
| Gross Profit | 517.94M | 937.60M | 809.60M | 427.27M | 378.38M |
| EBITDA | 277.99M | 276.26M | 230.65M | 215.55M | 199.46M |
| Net Income | 150.89M | 145.29M | 121.30M | 121.97M | 113.16M |
Balance Sheet | |||||
| Total Assets | 1.91B | 1.85B | 1.46B | 1.36B | 1.22B |
| Cash, Cash Equivalents and Short-Term Investments | 122.50M | 149.63M | 175.91M | 177.38M | 172.79M |
| Total Debt | 295.26M | 307.01M | 120.11M | 96.86M | 95.37M |
| Total Liabilities | 789.18M | 805.12M | 545.81M | 521.17M | 498.84M |
| Stockholders Equity | 1.13B | 1.04B | 900.30M | 839.33M | 724.93M |
Cash Flow | |||||
| Free Cash Flow | 103.41M | 134.97M | 77.60M | 45.41M | 79.13M |
| Operating Cash Flow | 195.65M | 204.22M | 118.64M | 98.98M | 126.29M |
| Investing Cash Flow | -199.55M | -428.69M | -121.87M | -54.83M | -51.21M |
| Financing Cash Flow | -5.53M | 138.59M | -2.56M | -34.76M | -91.69M |
Virbac SA Technical Analysis
Positive
359.00
Price Trends
354.49
Positive
354.40
Positive
343.81
Positive
Market Momentum
-0.22
Negative
53.68
Neutral
66.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:VIRP, the sentiment is Positive. The current price of 359 is above the 20-day moving average (MA) of 346.15, above the 50-day MA of 354.49, and above the 200-day MA of 343.81, indicating a bullish trend. The MACD of -0.22 indicates Negative momentum. The RSI at 53.68 is Neutral, neither overbought nor oversold. The STOCH value of 66.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:VIRP.
Virbac SA Peers Comparison
UnderperformOutperform
Sector (55)
FR:VIRP
Virbac SA
354.00
56.35
18.93%
FR:ERF
Eurofins Scientific
65.06
16.95
35.24%
FR:VETO
VETOQUINOL
78.30
0.83
1.07%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.